Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · BILL · 116th Congress · H.R. 19 (Introduced in House) — To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the... · Sec. 321

Sec. 321. Change conditions of first generic exclusivity to spur access and competition

322 words·~1 min read·/bill/116/hr/19/ih/section-321

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

Section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j)(5)(B)(iv) ) is amended— in subclause (I), by striking 180 days after and all that follows through the period at the end and inserting the following: 180 days after the earlier of— the date of the first commercial marketing of the drug (including the commercial marketing of the listed drug) by any first applicant; or the applicable date specified in subclause (III). ; and by adding at the end the following new subclause:
The applicable date specified in this subclause, with respect to an application for a drug described in subclause (I), is the date on which each of the following conditions is first met: The approval of such an application could be made effective, but for the eligibility of a first applicant for 180-day exclusivity under this clause. At least 30 months have passed since the date of submission of an application for the drug by at least one first applicant. Approval of an application for the drug submitted by at least one first applicant is not precluded under clause
(iii). No application for the drug submitted by any first applicant is approved at the time the conditions under items (aa), (bb), and
(cc)are all met, regardless of whether such an application is subsequently approved. . The Secretary of Health and Human Services shall— not later than 120 days after the date of enactment of this Act, publish, as appropriate and available, information sufficient to allow applicants to assess whether the conditions described in section 505(j)(5)(B)(iv)(III) of the Federal Food, Drug, and Cosmetic Act (as added by subsection (a)) are satisfied for all applications where the exclusivity period under clause (iv)(I) of section 505(j)(5)(B) of the Federal Food, Drug, and Cosmetic Act (as amended by such subsection) has not expired; and publish updates to such information to reflect the most recent information available to the Secretary.
Connectionstraces to 1
Traces to 1 document
Citation graph
cites case law
Sec. 321
Change conditions of first generic exclusivity to spur access and competition
Cites 1Cited by 0 across 0 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.